Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally

Paradigm Biocapital Advisors sold 3,766,393 shares of Erasca in Q1 2026, an estimated $44.52 million transaction, leaving it with 10,392,702 shares worth $168.15 million. The stake still represented 3.44% of 13F AUM, but the sale came after a massive 700%+ run in the stock and before later clinical and patent-related setbacks that triggered a sharp selloff. The filing is primarily a positioning update, with limited immediate market-wide impact.

Analysis

This is less a bearish read-through on ERAS and more a signal that a sophisticated biotech holder is monetizing duration after an extreme re-rating. In names like this, the first-order price move is often driven by data; the second-order move is driven by position unwinds and diminished marginal sponsorship once the easy gains are captured. The key issue is not whether the science is “good,” but whether the stock can keep compounding without the same quality of flow support that powered the move higher.

The more interesting setup is the gap between clinical optionality and litigation/AE headline risk. When a program is valued on binary future readouts, even a small probability increase in safety or IP disruption can compress multiple turns of market cap quickly because the right tail is already priced optimistically. That means the next 1-3 months are likely to trade more on event sequencing, patent updates, and any incremental trial transparency than on platform narrative.

For peers, this kind of de-risking can be a relative-positive for higher-quality RAS/MAPK or oncology names with cleaner balance sheets and less event risk, because capital tends to recycle within biotech rather than leave the space entirely. The market is likely underappreciating how fast sentiment can rotate from “story premium” to “prove-it discount” once a top holder is trimming into strength. The contrarian angle is that the pullback may be overdone if the company can show the adverse event was idiosyncratic and the IP overhang is contained; in that case, the setup becomes one of volatility compression rather than fundamental collapse.

Key Decisions for Investors

• Avoid initiating fresh long ERAS here; wait for post-event stabilization and a lower-volatility entry after the next catalyst, because the near-term skew is still dominated by headline risk over 1-3 months.
• For existing biotech exposure, rotate capital from ERAS into higher-quality peers with cleaner event profiles; pair long ACLX or RVMD against short ERAS to express relative quality without taking outright sector beta.
• Consider a tactical put spread on ERAS into the next clinical/legal catalyst window if implied volatility remains elevated; the setup offers asymmetric downside if another safety or IP headline emerges within weeks.
• If you want exposure to the oncology platform theme, prefer a basket approach over single-name risk for the next quarter; the idiosyncratic downside in ERAS is too large relative to the remaining upside until the program de-risks.
• Set a buy-watcher on ERAS only if it reclaims prior support after the next data point; that would indicate forced selling is exhausted and create a better risk/reward than chasing momentum now.